Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.34 |
| ▸ | UCHL1 | P09936 | 3/20 | 0.34 |
| ▸ | GSK3B | P49841 | 3/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.34 |
| ▸ | WNT1 | P04628 | 2/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL888912 | 0.86 | CYP3A4 (0.35) | USP30UCHL1GSK3BDYRK1AWNT1 | |
| SCHEMBL889126 | 0.86 | CYP3A4 (0.35) | USP30UCHL1GSK3BDYRK1AWNT1 | |
| SCHEMBL888977 | 0.83 | PRMT5 (0.43) | GSK3BDYRK1AWNT1GPR119PRMT5 | |
| SCHEMBL889005 | 0.81 | CYP3A4 (0.49) | — | |
| SCHEMBL14924575 | 0.79 | ALDH1A1 (0.43) | USP30UCHL1ALDH1A1CHEK2KDM4E | |
| SCHEMBL12104032 | 0.79 | ALDH1A1 (0.43) | USP30UCHL1ALDH1A1CHEK2KDM4E | |
| SCHEMBL888980 | 0.79 | USP30 (0.45) | USP30GPR119 | |
| SCHEMBL14924576 | 0.79 | ALDH1A1 (0.41) | USP30UCHL1GPR119ALDH1A1CHEK2 | |
| SCHEMBL16904938 | 0.79 | ALDH1A1 (0.41) | USP30UCHL1GPR119ALDH1A1CHEK2 | |
| SCHEMBL889122 | 0.78 | PRMT5 (0.48) | GSK3BDYRK1AWNT1GPR119PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759332-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | USP30 2645/4885UCHL1 2715/4885GSK3B 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.